A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease

Journal of Infectious Diseases

Volumn 175, Issue 1, 1997, Pages 16-25

  Boursnell, M E G ^a   Entwisle, C ^b   Blakeley, D ^b   Roberts, C ^b   Duncan, I A ^b   Chisholm, S E ^b   Martin, G M ^b   Jennings, R ^b   Ni Challanain D ^b   Sobek, I ^b   Inglis, S C ^b   McLean, C S ^b  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; GENE ACTIVATION; GENE DELETION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RECURRENT DISEASE; VIRUS INFECTION; VIRUS REPLICATION;

EID: 16944365192     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.1.16     Document Type: Article

References (19)

1. Corey L. Herpes simplex virus infections during the decade since the licensure of acyclovir. J Med Virol 1993;Suppl 1:7-12.
2. Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis SC, Minson AC. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994;68:927-32.
3. McLean CS, Erturk M, Jennings R, et al. Protective vaccination against primary and recurrent disease cause by herpes simplex virus type 2 using a genetically disabled herpes simplex type 1 virus. J Infect Dis 1994;170:1100-9.
4. Forrester A, Farrell H, Wilkinson G, Kaye J, Davis-Poynter N, Minson AC. Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol 1992;66:341-8.
5. Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 1982;146:397-404.
6. World Health Organization. WHO Cell banks of continuous cell lines for the production of biologicals. World Health Organ Tech Rep Ser 1989;786.
7. Wilkinson GW, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 1992;20:2233-9.
8. Brierley I, Rolley NJ, Jenner AJ, Inglis, SC. Mutational analysis of the RNA pseudoknot component of a coronavirus ribosomal frameshifting signal. J Mol Biol 1991;220:889-902.
9. Walboomers JMM, Ter Schegget J. A new method for the isolation of herpes simplex virus type 2 DNA. Virology 1976;74:256-8.
10. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987;7:2745-52.
11. Burke R L. Current developments in herpes simplex virus vaccines. Semin Virol 1993;4:187-97.
12. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155:914-20.
13. Stanberry LR, Burke RL, Myers MG. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J Infect Dis 1988;157:156-63.
14. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-3.
15. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
16. Hammerschlag MR, Gershon AA, Steinberg SP, Gelb LD. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989;160:535-7.
17. Nguyen LH, Knipe DM, Finberg RW. Replication defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 1992;66:7067-72.
18. Peeters B, Bouma A, de Bruin T, Moormann R, Gielkens A, Kimman T. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. Vaccine 1994;12:375-80.
19. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988;6:497-503.